The UK-based pharmaceutical company Flynn Pharma Ltd has written to Epilepsy Society's chief executive Clare Pelham to reassure her that they do not foresee any disruption to supply or availability of the epilepsy drug phenytoin sodium.

A letter in today's Times (9 December 2016) from Epilepsy Society's chief executive Clare Pelham calls on drug company Pfizer to give people with epilepsy a hard and fast guarantee that it will continue to manufacture phenytoin sodium capsules.

Epilepsy Society's new chief executive Clare Pelham stresses need for a balance in the price the NHS is charged for drugs as Pfizer is fined a record £84.2 million for its role in over-charging for an epilepsy drug.

Epilepsy Society

Epilepsy Society is the working name of The National Society for Epilepsy, registered charity number 206186

Every effort is made to ensure that all our information is correct and up to date. However, Epilepsy Society is unable to provide a medical opinion on specific cases. Responses to enquiries contain information relating to the general principles of investigation and management of epilepsy. Answers are not, and should not be assumed to be, direct medical advice and is not intended to be a substitute for medical guidance from your own doctors. Epilepsy Society and any third party cannot be held responsible for any actions taken as a result of using this service. Any references made to other organisations does not imply any endorsement by Epilepsy Society.